Objective: The aim of this systematic review and meta-analysis is to systematically collect, evaluate, and critically synthesize research findings on the effects of physical exercise on chemotherapy-induced peripheral neuropathy (CIPN).
Method: The Joanna Briggs Institute (JBI) methodology for systematic reviews was adopted for this study. We searched the Medline®, CINAHL, SportDiscus, and Scopus databases to identify relevant articles published from inception to March 2024.
J Biophotonics
January 2025
Objective: Evaluate the influence of photobiomodulation in a model of oral carcinogenesis induced by 4-nitroquinoline-n-oxide (4-NQO).
Subjective: Ninety-six Swiss mice received topical application of 1% 4-NQO on tongue dorsum, for 20 weeks. The tongue was subjected to photobiomodulation with red (71.
Background: Radiotherapy is one of the main treatments for head and neck cancer; however, due to its non-selectivity the glandular tissue can be affected. This scoping review aimed to identify the evidence about mesenchymal stem cell therapies for irradiated salivary gland regeneration.
Material And Methods: Two independent reviewers performed a literature search in MEDLINE/PubMed, Scopus, and Web of Science.
Background: Spinal immobilization, a widely used trauma prehospital intervention, is known to cause discomfort, yet little is known about interventions to reduce this discomfort.
Objective: This scoping review aims to evaluate prehospital interventions to reduce discomfort from spinal immobilization in adult trauma patients.
Method: This scoping review assessed prehospital pharmacological and nonpharmacological interventions to address discomfort from spinal immobilization in adult trauma patients.
Introduction: Cases involving invasive cervical root resorption (ICRR) in oncological patients are rare, in addition, follow-up of these patients has not yet been reported in the literature.
Objective: This study aims to present a literature review and report a case of denosumab as a possible cause of ICRR in a patient with breast cancer with 2 years of follow-up.
Case Report: A 39-year-old female with a history of luminal breast cancer was treated with denosumab semiannually for osteopenia with discontinuation 1 year ago.